Institutional Biosafety Committee (IBC)
Lewis & Clark’s Institutional Biosafety Policy ensures the protection of faculty, staff, students who generate, process, and dispose of potentially hazardous biological materials at Lewis & Clark, as well as others who may become exposed to biological hazards within the institutional environment. The Institutional Biosafety Committee (IBC) must review and approve all research involving recombinant DNA, synthetic nucleic acid molecules, infectious agents or toxins. The PI must submit an application to the IBC prior to research initiation.
Committee Membership (2020-21)
Nikolaus Loening, PhD - Professor of Chemistry, IBC Chair
Sarah Byers, PhD - Assistant Research Integrity Officer, Oregon Health & Science University
Jason Holmgren - Occupational Health & Safety Manager
Janis Lochner, Ph.D - Robert B. Pamplin Jr. Professor of Science
Jane Yates - Research Biosafety Officer, VA Portland Health Care System
Administered by the Sponsored Projects and Research Compliance Office. Contact: Kelly DelFatti, Assistant VP of SPARC at firstname.lastname@example.org
Institutional Official: David Reese, Vice President, Chief of Staff, General Counsel and Board Secretary
The IBC meets annually, usually in the spring. Minutes of IBC meetings are available upon request. Please contact email@example.com for more information.
Research involving biological materials requires additional training.
The following links will take you away from the L&C website.
- NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) - Frequently Asked Questions
- Experiments that are Exempt from the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) - Frequently Asked Questions